CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer

Acquired drug resistance leads to poor clinical outcome in high grade serous ovarian cancer (HGSOC). We have demonstrated the efficacy of the novel drug CX-5461 in HGSOC is mediated through destabilization of DNA replication forks. The data highlights the potential of CX-5461 in overcoming a general...

Descripción completa

Detalles Bibliográficos
Autores principales: Xuan, Jiachen, Pearson, Richard B., Sanij, Elaine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Author’s Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671053/
https://www.ncbi.nlm.nih.gov/pubmed/33235908
http://dx.doi.org/10.1080/23723556.2020.1805256
_version_ 1783610854721191936
author Xuan, Jiachen
Pearson, Richard B.
Sanij, Elaine
author_facet Xuan, Jiachen
Pearson, Richard B.
Sanij, Elaine
author_sort Xuan, Jiachen
collection PubMed
description Acquired drug resistance leads to poor clinical outcome in high grade serous ovarian cancer (HGSOC). We have demonstrated the efficacy of the novel drug CX-5461 in HGSOC is mediated through destabilization of DNA replication forks. The data highlights the potential of CX-5461 in overcoming a general mechanism of chemotherapeutic resistance.
format Online
Article
Text
id pubmed-7671053
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-76710532020-11-23 CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer Xuan, Jiachen Pearson, Richard B. Sanij, Elaine Mol Cell Oncol Author’s Views Acquired drug resistance leads to poor clinical outcome in high grade serous ovarian cancer (HGSOC). We have demonstrated the efficacy of the novel drug CX-5461 in HGSOC is mediated through destabilization of DNA replication forks. The data highlights the potential of CX-5461 in overcoming a general mechanism of chemotherapeutic resistance. Taylor & Francis 2020-08-31 /pmc/articles/PMC7671053/ /pubmed/33235908 http://dx.doi.org/10.1080/23723556.2020.1805256 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Author’s Views
Xuan, Jiachen
Pearson, Richard B.
Sanij, Elaine
CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer
title CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer
title_full CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer
title_fullStr CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer
title_full_unstemmed CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer
title_short CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer
title_sort cx-5461 can destabilize replication forks in parp inhibitor-resistant models of ovarian cancer
topic Author’s Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671053/
https://www.ncbi.nlm.nih.gov/pubmed/33235908
http://dx.doi.org/10.1080/23723556.2020.1805256
work_keys_str_mv AT xuanjiachen cx5461candestabilizereplicationforksinparpinhibitorresistantmodelsofovariancancer
AT pearsonrichardb cx5461candestabilizereplicationforksinparpinhibitorresistantmodelsofovariancancer
AT sanijelaine cx5461candestabilizereplicationforksinparpinhibitorresistantmodelsofovariancancer

Ejemplares similares